Breaking Finance News

AstraZeneca PLC (LON:AZN) stock price target held steady at 7,600.00GBX, issued a research note today by Societe Generale

In a report issued Wednesday September 13, 2017 Societe Generale hold steady the target of AstraZeneca PLC (LON:AZN) from 7,600.00GBX to 7,600.00GBX indicating a possible upside of 0.58%.

Previously on 9/13/2017, HSBC reported on AstraZeneca PLC (LON:AZN) held steady the target price at 4,100.00GBX. At the time, this indicated a possible downside of -0.15%.

Yesterday AstraZeneca PLC (LON:AZN) traded 0.72% higher at 4,825.00GBX. The company’s 50-day moving average is 4,580.96GBX and its 200-day moving average is 4,880.60GBX. The last closing price is down 0.91% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 2,143,676 shares of the stock were exchanged, down from an average trading volume of 2,217,780

See Chart Below

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has a 52 week low of 3,996.00GBX and a 52 week high of 5,520.00GBX with a P/E ratio of 16.15 The company’s market cap is currently 0 GBX.

In addition to Societe Generale reporting its target price, a total of 29 brokers have issued a report on the stock. The consensus target price is 61.96GBX with 4 brokers rating the stock a strong buy, 14 brokers rating the stock a buy, 13 brokers rating the stock a hold, 2 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

General Information About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.